{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:10:20Z","timestamp":1787688620291,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T00:00:00Z","timestamp":1478304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018753","name":"Parc Geneteg Cymru","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018753","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000311","name":"Tuberous Sclerosis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.neo.2016.12.008","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T16:47:19Z","timestamp":1484326039000},"page":"112-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2+\/\u2212 Mice Is Superior to Everolimus Alone"],"prefix":"10.1016","volume":"19","author":[{"given":"Jian","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina A.","family":"Samsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalin","family":"Narov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gallacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gallacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian R.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2016.12.008_bb0005","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/PAS.0000000000000237","article-title":"Renal cell carcinoma in tuberous sclerosis complex","volume":"38","author":"Yang","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.neo.2016.12.008_bb0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2016.12.008_bb0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1056\/NEJMc072500","article-title":"Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis","volume":"358","author":"Davies","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2016.12.008_bb0020","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.neo.2016.12.008_bb0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1752-1947-8-95","article-title":"The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report","volume":"8","author":"Kim","year":"2014","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.neo.2016.12.008_bb0030","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1067\/mjd.2002.120530","article-title":"Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms","volume":"46","author":"Arbiser","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.neo.2016.12.008_bb0035","doi-asserted-by":"crossref","first-page":"F560","DOI":"10.1152\/ajprenal.00569.2013","article-title":"Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy","volume":"307","author":"Siroky","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.neo.2016.12.008_bb0040","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1200\/JCO.2012.48.1960","article-title":"Sorafenib induced tumour response in a patient with metastatic epithelioid angiomyolipoma","volume":"32","author":"Lee","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2016.12.008_bb0045","doi-asserted-by":"crossref","first-page":"E542","DOI":"10.5489\/cuaj.2823","article-title":"Malignant epitheloid angiomyolipoma of the kidney in a child treated with sunitinib, everolimus and axitinib","volume":"9","author":"Citak","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.neo.2016.12.008_bb0050","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/hmg\/ddi190","article-title":"A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma","volume":"14","author":"Wilson","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neo.2016.12.008_bb0055","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI7319","article-title":"Tsc2(+\/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background","volume":"104","author":"Onda","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neo.2016.12.008_bb0060","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/onc.2014.17","article-title":"Renal tumours in a Tsc2(+\/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin","volume":"34","author":"Yang","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2016.12.008_bb0065","first-page":"5173","article-title":"Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin","volume":"63","author":"El-Hashemite","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.neo.2016.12.008_bb0070","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.ejrad.2011.06.054","article-title":"T2 weighted MRI for assessing renal lesions in transgenic mouse models of tuberous sclerosis","volume":"81","author":"Kalogerou","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.neo.2016.12.008_bb0075","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/onc.2014.164","article-title":"mTORC1 drives HIF-1\u03b1 and VEGF-A signalling via multiple mechanisms involving 4E-BP1,S6K1 and STAT3","volume":"34","author":"Dodd","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2016.12.008_bb0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/2193-1801-3-120","article-title":"Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review","volume":"3","author":"Gkogkou","year":"2014","journal-title":"Springerplus"},{"key":"10.1016\/j.neo.2016.12.008_bb0085","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/ijc.24767","article-title":"Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer","volume":"126","author":"Singhal","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.neo.2016.12.008_bb0090","doi-asserted-by":"crossref","first-page":"100","DOI":"10.21037\/atm.2016.01.31","article-title":"Combination therapy for metastatic renal cell carcinoma","volume":"4","author":"Buonerba","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.neo.2016.12.008_bb0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11523-015-0416-3","article-title":"Lenvatinib: A Review in Refractory Thyroid Cancer","volume":"11","author":"Frampton","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.neo.2016.12.008_bb0100","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised,phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neo.2016.12.008_bb0105","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S1470-2045(15)00543-4","article-title":"Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma","volume":"17","author":"Motzer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neo.2016.12.008_bb0110","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1056\/NEJMcibr1406613","article-title":"Molecular basis of giant cells in tuberous sclerosis complex","volume":"371","author":"Kwiatkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2016.12.008_bb0115","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/carcin\/bgs203","article-title":"Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA","volume":"33","author":"Gulhati","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.neo.2016.12.008_bb0120","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/1078-0432.CCR-12-2293","article-title":"The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models","volume":"19","author":"Pignochino","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2016.12.008_bb0125","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.2353\/ajpath.2006.050711","article-title":"Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib(BAY43-9006)","volume":"169","author":"Murphy","year":"2006","journal-title":"Am J Pathol"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558616302573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558616302573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:05:04Z","timestamp":1761483904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558616302573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1476558616302573"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2016.12.008","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2+\/\u2212 Mice Is Superior to Everolimus Alone","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2016.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Inc. on behalf of SOCIETY.","name":"copyright","label":"Copyright"}]}}